SCHEMBL15314945

SCHEMBL15314945

CC[C@]1(c2ccccc2C)C(=O)N(C)c2ccccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.47
MAPT P10636 3/20 0.45
LMNA P02545 3/20 0.45
KDM4E B2RXH2 1/20 0.45
HCRTR1 O43613 1/20 0.45
RAD52 P43351 1/20 0.44
TDP1 Q9NUW8 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALDH1A1 P00352 3/20 0.43
PKM P14618 2/20 0.43
MAPK1 P28482 1/20 0.40
HTR7 P34969 1/20 0.40
TSHR P16473 1/20 0.39
CBX7 O95931 2/20 0.38
CDY1; CDY1B Q9Y6F8 2/20 0.38
ADAMTS5 Q9UNA0 1/20 0.38
CDYL2 Q8N8U2 1/20 0.38
CDYL Q9Y232 1/20 0.38
OPRM1 P35372 1/20 0.38
OPRK1 P41145 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18588965 0.81 ELANE (0.37) ELANEMAPTLMNAKDM4EHCRTR1
SCHEMBL15314951 0.79 TSHR (0.43) MAPTLMNAKDM4EHCRTR1ALDH1A1
SCHEMBL15314950 0.79 TSHR (0.50) MAPTLMNAKDM4EMAPK1TSHR
SCHEMBL2489202 0.75 HTR7 (0.56) ELANEMAPTLMNAKDM4EHCRTR1
SCHEMBL15314955 0.74 RAB9A (0.53) MAPTLMNAKDM4EHCRTR1RAD52
SCHEMBL29083889 0.74 MAPT (0.58) MAPTLMNAKDM4EHCRTR1RAD52
SCHEMBL28250863 0.73 MAPT (0.50) ELANEMAPTLMNAKDM4EHCRTR1
SCHEMBL25890248 0.72 RAD52 (0.68) MAPTLMNAKDM4EHCRTR1RAD52
SCHEMBL31294849 0.72 MEN1 (0.50) ELANEMAPTLMNAKDM4EHCRTR1
SCHEMBL14691615 0.71 LMNA (0.50) MAPTLMNAKDM4EHCRTR1RAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066777-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2017-03-09 US disclosed
US-9487535-B2 Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2016-11-08 US disclosed
US-20130274483-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS PACIRA PHARMACEUTICALS, INC. 2013-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066777-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS OPRK1, OPRL1, PKD2 ELANE 4209/4885MAPT 2596/4885LMNA 3253/4885
US-20130274483-A1 ASYMMETRIC SYNTHESES FOR SPIRO-OXINDOLE COMPOUNDS USEFUL AS THERAPEUTIC AGENTS OPRK1, OPRL1, PKD2 ELANE 4209/4885MAPT 2596/4885LMNA 3253/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.